A Randomized Controlled Clinical Study for Traditional Chinese Medicine to Improve the Clinical Benefit Rate of Advanced Esophageal Cancer
- Conditions
- Esophageal cancerM8000/3
- Registration Number
- ITMCTR2000003504
- Lead Sponsor
- Henan Province Hospital of TCM
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
1. Meet the diagnostic criteria of Chinese and Western medicine;
2. Esophageal cancer patients who cannot undergo surgery, radiotherapy, chemotherapy or disease progression after chemotherapy;
3. Gender and age are not limited;
4. The estimated survival time was more than 20 days;
5. KPS score >= 40;
6. Those who could take traditional Chinese medicine orally before treatment;
7. The patient voluntarily signs the informed consent with the informed consent.
1. Pregnant and lactating women;
2. Patients with mental illness who are difficult to cooperate with treatment;
3. Allergy to drugs;
4. Patients with severe liver, kidney, heart and hematopoietic system diseases;
5. There was no definite pathological diagnosis;
6. Have participated in other clinical research;
7. According to the researcher's judgment, other diseases or conditions that reduce the possibility of enrollment or complicate the enrollment, such as frequent changes in working environment and unstable living environment and other situations that are likely to cause patients to loss to follow-up.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method TCM syndrome score;Survival rate of 42 days;KPS score;42 days quality of life;
- Secondary Outcome Measures
Name Time Method Serum tumor markers (CEA, SCC, CA153, CA125, CA199);Safety indicator;T lymphocyte subsets (CD3, CD4, CD8, CD16, CD56), regulatory T cells (CD4 +, CD25 +, Foxp3);Remission of local lesions;